Rajiv Kumar

Dr. Rajiv Kumar


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2020 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
SNSusanna S Ng
Susanna S Ng
FRFabian De Labastida Rivera
Fabian De Labastida Rivera
JYJuming Yan
Juming Yan
DCDillon Corvino
Dillon Corvino
IDIndrajit Das
Indrajit Das
CEChristian R. Engwerda
Christian R. Engwerda

1 October 2011 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
SGShalini Gautam
Shalini Gautam
RKRajiv Kumar
Rajiv Kumar
RMRadheshyam Maurya
Radheshyam Maurya
SNSusanne Nylén
Susanne Nylén
NANasim Ansari
Nasim Ansari
DSDavid Sacks
David Sacks
The mechanisms underlying the failure to contain the growth of Leishmania parasites in human visceral leishmaniasis (VL) are not understood. L donovani amastigotes were quantified in cultured splenic aspirate cells to assess the function of IL-10 in lesional tissue ex vivo. In 67 patients with active VL, IL-10 neutralization promoted parasite killing in 73% and complete clearance in 30%, while 18% had more parasites and 9% did not change. The splenic cells secreted increased levels of both tumor necrosis factor α (TNFα) and interferon γ (IFNγ) under IL-10-neutralizing conditions. These findings provide direct support for targeting IL-10 as an approach to therapy in human VL.

1 January 2012 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
RKRajiv Kumar
Rajiv Kumar
SNSusanne Nylén
Susanne Nylén
Visceral leishmaniasis (VL), commonly known as kala-azar, is caused by Leishmania donovani and Leishmania infantum (Leishmania chagasi in the Americas). These Leishmania species infect macrophages throughout the viscera, and parasites are typically found in the spleen, liver, and bone marrow. Patients with active disease typically exhibit marked immunosuppression, lack reactivity to the Leishmania skin test (LST), a delayed type hypersensitivity test, and their peripheral blood mononuclear cells (PBMC) fail to respond when stimulated with leishmanial antigens in vitro. However, most people infected with visceralizing species of Leishmania never develop disease. Understanding immune failure and the underlying immune mechanism that lead to disease as well as control of infection are key questions for research in this field. In this review, we discuss immunological events described in human and experimental VL and how these can affect the outcome of infection.

14 March 2014 in Clinical & Translational Immunology
Verified
Journal Article
Open access
RKRajiv Kumar
Rajiv Kumar
CEChristian Engwerda
Christian Engwerda
Leishmaniasis is a parasitic disease that encompasses a range of clinical manifestations affecting people in tropical and subtropical regions of the world. Epidemiological and experimental data indicate that protection from disease can be achieved in most people. In addition, we know how the host immune system must respond to infection in order to control parasite growth. However, there is still no vaccine for use in humans. Here, we review our understanding of host immunity following Leishmania infection and also discuss recent advances in the development of vaccines to prevent leishmaniasis, highlighting a new promising approach that targets the parasite hemoglobin receptor.

10 July 2014 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
RFRebecca J Faleiro
Rebecca J Faleiro
RKRajiv Kumar
Rajiv Kumar
LHLouise M Hafner
Louise M Hafner
CEChristian R Engwerda
Christian R Engwerda
Visceral leishmaniasis is a chronic parasitic disease associated with severe immune dysfunction. Treatment options are limited to relatively toxic drugs, and there is no vaccine for humans available. Hence, there is an urgent need to better understand immune responses following infection with Leishmania species by studying animal models of disease and clinical samples from patients. Here, we review recent discoveries in these areas and highlight shortcomings in our knowledge that need to be addressed if better treatment options are to be developed and effective vaccines designed.

6 August 2013 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
SGShalini Gautam
Shalini Gautam
RKRajiv Kumar
Rajiv Kumar
NSNeetu Singh
Neetu Singh
ASAbhishek Kumar Singh
Abhishek Kumar Singh
MRMadhukar Rai
Madhukar Rai
SNSusanne Nylén
Susanne Nylén
Little is known about CD8 T cells in human visceral leishmaniasis (VL) and it is unclear if these cells have a protective, pathological and/or suppressive function. In experimental VL CD8 T cells have been shown to contribute to parasite control and play an important role in vaccine-generated immunity. To better understand the role of CD8 T cells in human VL, we examined molecules associated with anergy and cytotoxic T lymphocytes (CTL) in peripheral blood mononuclear cells (PBMC) and splenic aspirates (SA), and in CD8 cells derived from these tissues. Gene and surface marker expression suggest that splenic CD8 cell predominantly display an anergic phenotype, whereas CD8-PBMC have features of both anergic cells and CTLs. CD8 cells contribute to the baseline IFNγ levels in whole blood (WB) and SA cultures, but not to the Leishmania induced IFNγ release that is revealed using WB cultures. Blockade of CTLA-4 or PD1 had no effect on IFNγ production or parasite survival in SA cultures. Following cure, CD8 T cells contribute to the Leishmania induced IFNγ production observed in Leishmania stimulated cell cultures. We suggest CD8 T cells are driven to anergy/exhaustion in human VL, which affect their ability to contribute to protective immune responses.